Hazar, VolkanKarasu, Gulsun TezcanUygun, VedatOzbek, NamikKarakukcu, MusaOzturk, GulyuzAksoylar, Serap2025-05-102025-05-1020201042-81941029-240310.1080/10428194.2020.1716220https://doi.org/10.1080/10428194.2020.1716220https://hdl.handle.net/20.500.14720/5959Kocak, Ulker/0000-0002-8701-5285; Karakukcu, Musa/0000-0003-2015-3541; Karasu, Gulsun/0000-0001-5700-5919; Unal, Ekrem/0000-0002-2691-4826; Ileri, Talia/0000-0002-0244-353X; Akcay, Arzu/0000-0003-0841-1667; Daloglu, Hayriye/0009-0008-6996-0292; Karagun, Barbaros Sahin/0000-0002-7678-5524; Aksu, Tekin/0000-0003-4968-109X; Uygun, Vedat/0000-0003-3257-7798; Yesilipek, M.Akif/0000-0002-4514-8637We examined outcomes of 51 pediatric patients with relapsed acute leukemia (AL) who underwent a second allogeneic hematopoietic stem cell transplantation (alloHSCT). After a median follow-up of 941 days (range, 69-2842 days), leukemia-free survival (LFS) and overall survival (OS) at 3 years were 26.6% and 25.6%, respectively. The nonrelapse mortality rate (NMR) and cumulative incidence of relapse (CIR) were 36.4% and 42.4%, respectively. The Cox regression analysis demonstrated that the risk factors at second transplantation for predicting limited LFS were active disease (hazard ratio (HR) = 5.1), reduced intensity conditioning (RIC) (HR = 5.0), matched unrelated donor (MUD) (HR = 3.4) and performance score <80 (HR = 3.2). Pediatric patients with AL who relapsed after their first alloHSCT may survive with a second alloHSCT. Disease status, conditioning intensity, donor type, and performance score at the second transplantation are the relevant risk factors. A score based on these factors may predict the results of the second transplantation.eninfo:eu-repo/semantics/closedAccessPosttransplantation RelapseSecond TransplantationAcute LeukemiaChildrenArticle616Q3Q31465147432037917WOS:000513301500001